Oncology CRO Services
Take advantage of InnoSer’s expertise oncology and portfolio spanning in vitro to in vivo research services
Preclinical Immunology Research with InnoSer
✓ Powerful Imaging Techniques
✓ Smart Pathological Assessments
✓ Pharmacology Expertise
✓ Fast Study Initiation
✓ Tailored Study Designs
✓ Dedicated Research Co-oridnators
InnoSer offers integrated oncology CRO services portfolio spanning from in vitro to in vivo research services. Our experts facilitate a collaborative approach ensuring we accelerate your drug development process using in-depth knowledge of the models in our portfolio to provide reliable experimental data.
InnoSer’s oncology expert team possesses relevant experience to work with multiple oncology therapy types ranging from novel delivery methods, oncology vaccines, immuno-oncology targets, combination therapy, small molecules, biologics to cell and gene therapy approaches. Complemented by our drug development service offering (such as target validation, biomarker identification and validation, as well as PK/PD profiling), InnoSer team works with you to accelerate your drug development at every stage.
Preclinical Oncology Model Catalogue
Immuno-Oncology In Vitro Assays
InnoSer offers oncology CRO services using cancer-associated tumor and microenvironment-associated cell lines (human and rodent)
Patient-derived Xenograft (PDX) Mouse Models
Recapitulate the tumor and patient heterogeneity using patient-derived xenograft (PDX) mouse models
Syngeneic Mouse Models
InnoSer offers contract research services using subcutaneous and orthotopic syngeneic mouse models
Humanized Mouse Models for Immuno-Oncology Research
Humanized mouse models represent one of the most translationally relevant immuno-oncology tools
Cell Line-derived Xenograft (CDX) Mouse Models
CDX models represent one of the first steps to evaluate the efficacy using in vivo models of human cancer
Patient-derived Organoids (Tumoroids)
Access InnoSer’s high-throughput drug screening capabilities
Don’t See Your Model? We Can Help!
Our experts specialize in tailored solutions to meet your unique research needs. Let’s discuss how we can support your project.
The People Behind Your Research
Céline Erens, PhD, Immunology Study Director
An expert team led by our immuno-oncology study director, Céline Erens helps you choose the right tools and set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Oncology Board Members
Prof. Dr. Esther Wolfs
A member of InnoSer’s Scientific Advisory Board, Dr. Wolfs is a leading researcher in stem cell therapy. Currently a professor at the University of Hasselt, Ester uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease type 1A.
MD, PhD Marije Slingerland
A member of InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.
Preclinical Oncology with InnoSer
Powered by imaging capabilities
In vivo imaging (bioluminescence imaging and/or ultrasound) is a valuable tool for collecting mid-study data in animal studies. These non-invasive methods can be applied with high sensitivity and in real-time. With InnoSer’s imaging capabilities, you can now track tumorigenicity, tumor progression, metastasis, tumor volume and quantify your immune cell populations. Read more >>
Smart pathological assessment
Enhance the translation value of your cancer research with a histopathological assessment of clinically relevant biomarkers. We can provide insights into the tumor microenvironment, inflammation, and fibrosis thanks to our in-house vetererinary and clinical pathologists. Supported by digital workflows for efficient and accurate results our histopathology services will see your research enhanced through technology. Read more >>
Fast study initiation with timely and insightful updates
Tumor models are quickly set up upon agreement with our dedicated oncology study team. Timely updates enable you to closely follow the progression of your project. Supported by close communication channels to our experts that help inform and guide your research, we can consult on relevant endpoint analysis and help guide and inform your research with our niche expertise.
FAQ
What is a preclinical oncology CRO?
- Offer expert advice on a wide range of studies, including pharmacology, early-stage toxicology, and efficacy testing
- Test the therapeutic profile of the novel investigational compounds
- Develop and validate new cancer models
- Conduct efficacy studies in xenograft, syngeneic, and humanized mouse models
Partnering with a preclinical oncology CRO offers access to cutting-edge resources, speeds up drug development, and allows your team to focus on its core objectives without the need to set up complex systems in your own lab. Discuss how InnoSer can support your preclinical oncology research goals.
What is a mouse xenograft model?
Mouse xenograft models represent a research tool established via transplantation of cell line-derived xenograft (CDX) or patient-derived xenograft (PDX) into immunodeficient or humanized mice. Mouse xenografts are the most frequently used models for testing therapeutic efficacy due to their reliability and relevance in cancer research.
Read more about InnoSer’s capabilities with CDX and PDX mouse models.
Why should I choose InnoSer as my partner CRO for preclinical immuno oncology research?
- Flexible study start-up timelines to fit your research schedule.
- Comprehensive immuno-oncology service portfolio integrated with pharmacology expertise.
- Capacity to run multiple studies simultaneously, ensuring efficient project execution.
- Ability to develop new models tailored to your specific research requirements.
- Collaborative study design and hands-on support from dedicated study directors.
How can InnoSer's integrated preclinical immuno-oncology services help advance my preclinical research?
- Integrated drug development studies: Including PK/PD profiling and early-stage efficacy studies.
- In vitro models: Featuring 2D cell lines, 3D cultures, and organoids for high-throughput screening.
- In vivo models: Syngeneic, CDX, PDX, and humanized mouse models.
- Advanced techniques: Flow cytometry, histopathology, and in vivo imaging (e.g., ultrasound and bioluminescence imaging).
- Our integrated approach ensures seamless transition between stages of preclinical research and supports optimal decision-making.
What oncology models should I choose for my research?
Unlock the Right Tools for Your Research.
Explore and compare our oncology platforms to identify the perfect model for your study needs.
Stay Curious: More Articles to Explore
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Tumor microenvironment (TME) multiplex immunophenotyping analyses
The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com